Alvin Chen, MD
Cardiovascular Disease (Cardiology) · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (650) 691-6174 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A143869 · Current
Licensed to practise in California · since 2016 · expires 2027-12-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$312,983
Medicare paid this office $312,983 for 1,446 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 304 | $61,020 | $188 |
| Return visit (30+ min) | 298 | $56,125 | $115 |
| Long return visit (40+ min) | 131 | $30,549 | $163 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 20 | $20,115 | $1,006 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $18,873 | $105 |
See all 35 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 304 | $61,020 | $188 |
| Return visit (30+ min) | 298 | $56,125 | $115 |
| Long return visit (40+ min) | 131 | $30,549 | $163 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 20 | $20,115 | $1,006 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $18,873 | $105 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 64 | $14,700 | $230 |
| Ct scan of blood vessels and grafts of heart with contrast | 47 | $13,867 | $295 |
| New patient visit (60+ min) | 70 | $13,372 | $191 |
| New patient visit (45+ min) | 88 | $12,264 | $139 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 175 | $10,309 | $56 |
| Critical care, first 30-74 minutes | 14 | $8,447 | $180 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $7,900 | $144 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 579 | $7,177 | $12 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 307 | $6,594 | $15 |
| Ultrasound of heart with probe in esophagus, with report | 50 | $4,459 | $89 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 79 | $1,735 | $21 |
| Programming of dual lead pacemaker system | 18 | $1,564 | $68 |
| 3d radiographic procedure with computerized image postprocessing | 47 | $1,548 | $33 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $1,268 | $24 |
| Ct scan of blood vessels and grafts of heart with contrast | 12 | $1,221 | $102 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 20 | $1,206 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 24 | $1,191 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 79 | $1,008 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $953 | $64 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 24 | $924 | $39 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $749 | $16 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $626 | $30 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 28 | $472 | $17 |
| Heart muscle strain imaging | 13 | $468 | $36 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 47 | $419 | $0 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 28 | $318 | $11 |
| Ultrasound of heart blood flow, valves and chambers | 17 | $271 | $16 |
| 3d radiographic procedure | 24 | $196 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 54 | $150 | $3 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $50 | $3 |
Who their Medicare patients are
1,446 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 19% · Women 53% · Also on Medicaid 13% · Health risk score 1.19. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 73% · Coronary heart disease 34% · Atrial fibrillation 28% · Diabetes 27% · Chronic kidney disease 27% · Heart failure 20% · Cancer 20% · Depression 15% · COPD 11% · Stroke 10% · Dementia 8%.
The office billed $1,403,723, Medicare allowed $418,891 and paid $312,983; for 7,736 services of 53 kinds; $507 of it was for drugs given in the office and $312,476 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,446 | 7,736 | 77 | 1.19 | $1,403,723 | $312,983 |
| 2023 | 1,296 | 5,652 | 77 | 1.14 | $1,091,028 | $258,215 |
| 2022 | 1,009 | 4,181 | 77 | 1.19 | $826,098 | $194,147 |
| 2021 | 482 | 998 | 77 | 1.11 | $336,437 | $91,460 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 219 | $46,468 | $205 |
| Return visit (30+ min) | 215 | $41,456 | $115 |
| Long return visit (40+ min) | 71 | $17,497 | $165 |
| New patient visit (45+ min) | 123 | $17,304 | $141 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 64 | $14,923 | $230 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 29 | $13,405 | $462 |
| New patient visit (60+ min) | 61 | $12,373 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $11,947 | $108 |
| Ct scan of blood vessels and grafts of heart with contrast | 34 | $10,190 | $300 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 156 | $10,127 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 591 | $8,255 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,156 | $160 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $4,268 | $76 |
| Critical care, first 30-74 minutes | 14 | $4,243 | $184 |
| Injection, regadenoson, 0.1 mg | 23 | $4,243 | None |
| Ultrasound of heart with probe in esophagus, with report | 35 | $3,329 | $95 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 40 | $2,446 | $60 |
| Programming of dual lead pacemaker system | 16 | $1,761 | $77 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 77 | $1,715 | $22 |
| 3d radiographic procedure with computerized image postprocessing | 28 | $949 | $34 |
| Heart rhythm recording of continous external ekg over 8-15 days | 75 | $943 | $13 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 22 | $932 | $42 |
| Ultrasound of heart blood flow, valves and chambers | 35 | $559 | $16 |
| Heart muscle strain imaging | 13 | $519 | $40 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $347 | $20 |
| 3d radiographic procedure | 37 | $342 | $9 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 35 | $327 | $0 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 16 | $216 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 39 | $109 | $3 |
2022: 24 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 131 | $26,502 | $196 |
| Return visit (30+ min) | 133 | $24,564 | $112 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 33 | $15,476 | $469 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 18 | $15,147 | $842 |
| Long return visit (40+ min) | 50 | $12,485 | $156 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 49 | $10,763 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $10,742 | $89 |
| New patient visit (45+ min) | 72 | $10,445 | $145 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 160 | $9,808 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,428 | $173 |
| Ct scan of blood vessels and grafts of heart with contrast | 24 | $6,920 | $288 |
| Critical care, first 30-74 minutes | 12 | $6,199 | $188 |
| New patient visit (60+ min) | 32 | $6,073 | $190 |
| Injection, regadenoson, 0.1 mg | 31 | $5,851 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 33 | $5,609 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 466 | $5,501 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 43 | $2,726 | $63 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 73 | $1,788 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 73 | $1,119 | $14 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 19 | $712 | $37 |
| Ultrasound of heart, follow-up | 12 | $416 | $23 |
| 3d radiographic procedure | 43 | $359 | $8 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 22 | $176 | $0 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $54 | $3 |
2021: 16 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 61 | $13,477 | $214 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 20 | $10,444 | $522 |
| New patient visit (60+ min) | 43 | $9,108 | $212 |
| Long return visit (40+ min) | 33 | $8,379 | $175 |
| New patient visit (45+ min) | 42 | $6,688 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,786 | $95 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 21 | $5,198 | $248 |
| Return visit (30+ min) | 36 | $5,166 | $123 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $4,676 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,662 | $183 |
| Injection, regadenoson, 0.1 mg | 17 | $3,244 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 211 | $3,178 | $15 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 17 | $3,022 | $89 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 31 | $2,045 | $66 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 55 | $1,384 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 55 | $920 | $17 |
Medicaid work
$4,188 in 2024
Medicaid paid $4,188 for 490 billed services this clinician did in 2024, up to 168 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 402 | $2,356 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 63 | $922 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 25 | $910 |
| 2024 | 490 | 3 | 168 | $4,188 |
| 2023 | 398 | 3 | 87 | $4,883 |
| 2022 | 163 | 2 | 47 | $1,569 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 298 | $1,922 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $1,655 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 85 | $1,305 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 108 | $788 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 55 | $780 |
Drugs they prescribed that Part D paid
$801,549
Pharmacies billed $801,549 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,440) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,012 generic and 428 brand-name prescriptions · $801,549 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 242 | $343,516 | $1,419 |
| Jardiance | 72 | $91,945 | $1,277 |
| Entresto | 37 | $45,608 | $1,233 |
| Repatha Sureclick | 17 | $19,250 | $1,132 |
| Xarelto | 11 | $18,278 | $1,662 |
See all 29 drugs
| Eliquis | 242 | $343,516 | $1,419 |
| Jardiance | 72 | $91,945 | $1,277 |
| Entresto | 37 | $45,608 | $1,233 |
| Repatha Sureclick | 17 | $19,250 | $1,132 |
| Xarelto | 11 | $18,278 | $1,662 |
| Praluent | 12 | $9,811 | $818 |
| Metoprolol | 310 | $4,035 | $13 |
| Rosuvastatin | 254 | $4,010 | $16 |
| Ezetimibe | 76 | $3,291 | $43 |
| Olmesartan Medoxomil | 147 | $2,990 | $20 |
| Torsemide | 74 | $1,802 | $24 |
| Atorvastatin | 173 | $1,727 | $10 |
| Carvedilol | 150 | $1,699 | $11 |
| Amlodipine Besylate | 239 | $1,439 | $6 |
| Losartan | 69 | $711 | $10 |
| Lisinopril | 43 | $641 | $15 |
| Hydralazine | 24 | $509 | $21 |
| Amiodarone | 36 | $475 | $13 |
| Valsartan | 23 | $428 | $19 |
| Diltiazem 24hr Er (Cd) | 18 | $411 | $23 |
| Pravastatin | 43 | $408 | $9 |
| Clopidogrel | 18 | $404 | $22 |
| Spironolactone | 32 | $293 | $9 |
| Furosemide | 34 | $260 | $8 |
| Chlorthalidone | 13 | $246 | $19 |
| Isosorbide Mononitrate Er | 17 | $189 | $11 |
| Metoprolol | 35 | $157 | $4 |
| Pantoprazole | 17 | $156 | $9 |
| Hydrochlorothiazide | 14 | $71 | $5 |
Year by year
| 2024 | 2,440 | 421 | 0% (0) | 18% | $801,549 |
| 2023 | 1,532 | 318 | 0% (0) | None | $356,707 |
| 2022 | 768 | 170 | 0% (0) | 18% | $188,750 |
| 2021 | 307 | 98 | 0% (0) | 17% | $61,435 |
| 2020 | 168 | 54 | 0% (0) | 15% | $25,168 |
| 2019 | 165 | 46 | 0% (0) | 13% | $20,623 |
| 2018 | 31 | None | 0% (0) | None | $16,362 |
| 2017 | 18 | None | None | 0% | $11,951 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Eliquis | 150 | $225,800 | $1,505 |
| Jardiance | 36 | $48,227 | $1,340 |
| Entresto | 12 | $11,426 | $952 |
| Metoprolol | 213 | $5,438 | $26 |
| Carvedilol Er | 11 | $5,222 | $475 |
| Rosuvastatin | 144 | $3,848 | $27 |
| Olmesartan Medoxomil | 63 | $3,293 | $52 |
| Atorvastatin | 120 | $2,176 | $18 |
| Amlodipine Besylate | 154 | $1,865 | $12 |
| Torsemide | 40 | $1,771 | $44 |
| Amiodarone | 37 | $1,722 | $47 |
| Carvedilol | 95 | $1,699 | $18 |
| Valsartan | 15 | $1,497 | $100 |
| Ezetimibe | 30 | $1,430 | $48 |
| Losartan | 51 | $935 | $18 |
| Hydralazine | 16 | $890 | $56 |
| Diltiazem 24hr Er (Cd) | 15 | $834 | $56 |
| Isosorbide Mononitrate Er | 23 | $692 | $30 |
| Pravastatin | 25 | $568 | $23 |
| Lisinopril | 34 | $528 | $16 |
| Pantoprazole | 16 | $347 | $22 |
| Clopidogrel | 17 | $344 | $20 |
| Furosemide | 42 | $232 | $6 |
| Spironolactone | 17 | $217 | $13 |
| Metoprolol | 28 | $76 | $3 |
2022: 17 drugs
| Eliquis | 99 | $142,730 | $1,442 |
| Repatha Sureclick | 12 | $6,643 | $554 |
| Metoprolol | 131 | $3,646 | $28 |
| Rosuvastatin | 65 | $1,736 | $27 |
| Atorvastatin | 76 | $1,473 | $19 |
| Clopidogrel | 29 | $730 | $25 |
| Amlodipine Besylate | 68 | $702 | $10 |
| Carvedilol | 37 | $647 | $17 |
| Olmesartan Medoxomil | 18 | $464 | $26 |
| Isosorbide Mononitrate Er | 12 | $445 | $37 |
| Losartan | 25 | $434 | $17 |
| Amiodarone | 13 | $433 | $33 |
| Torsemide | 16 | $360 | $22 |
| Pantoprazole | 13 | $227 | $17 |
| Furosemide | 18 | $182 | $10 |
| Lisinopril | 12 | $139 | $12 |
| Metoprolol | 12 | $64 | $5 |
2021: 10 drugs
| Eliquis | 29 | $40,056 | $1,381 |
| Xarelto | 14 | $11,621 | $830 |
| Metoprolol | 43 | $1,239 | $29 |
| Atorvastatin | 41 | $693 | $17 |
| Rosuvastatin | 16 | $397 | $25 |
| Amlodipine Besylate | 27 | $285 | $11 |
| Isosorbide Mononitrate Er | 11 | $257 | $23 |
| Carvedilol | 20 | $242 | $12 |
| Losartan | 13 | $239 | $18 |
| Furosemide | 12 | $99 | $8 |
2020: 6 drugs
| Eliquis | 16 | $15,390 | $962 |
| Metoprolol | 39 | $876 | $22 |
| Atorvastatin | 18 | $341 | $19 |
| Carvedilol | 18 | $182 | $10 |
| Losartan | 12 | $165 | $14 |
| Amlodipine Besylate | 19 | $160 | $8 |
2019: 5 drugs
| Amiodarone | 13 | $2,337 | $180 |
| Metoprolol | 28 | $785 | $28 |
| Atorvastatin | 21 | $721 | $34 |
| Carvedilol | 14 | $171 | $12 |
| Amlodipine Besylate | 13 | $86 | $7 |
2018: 1 drug
| Atovaquone | 15 | $14,889 | $993 |
2017: 1 drug
| Atovaquone | 11 | $11,376 | $1,034 |
Money from drug and device companies
$1,088 in 2025
| 2025 | 6 | 9 | None | $1,088 |
| 2024 | 5 | 8 | None | $678 |
| 2023 | 4 | 11 | None | $1,570 |
| 2022 | 6 | 8 | None | $909 |
| 2021 | 3 | 4 | None | $112 |
| 2020 | 1 | 12 | None | $1,549 |
| 2019 | 2 | 15 | None | $1,406 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $390 | 3 payments
|
| Amgen | Repatha | $250 | 2 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $169 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $152 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $107 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $21 | 1 payment
|
See all 9 published payments
| Amgen | Meals · 2025-12-17 | Repatha | $125 |
| Heartflow | Meals · 2025-10-23 | Ffrct | $192 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-04 | Jardiance | $107 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-16 | Lifevest | $21 |
| Amgen | Meals · 2025-04-23 | Repatha | $125 |
| Tactile Systems Technology | Meals · 2025-03-21 | Flexitouch Plus | $152 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Medtronic | Meals · 2025-03-04 | Aurora Ev-Icd Mri Surescan | $169 |
| Heartflow | Meals · 2025-02-18 | Ffrct | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $678
| Heartflow | Ffrct | $300 | 2 payments
|
| Novo Nordisk | Wegovy | $122 | 1 payment
|
| Amgen | Repatha | $107 | 1 payment
|
| Boston Scientific | Watchman Flx | $83 | 2 payments
|
| Ge Healthcare | None | $67 | 2 payments
|
2023: $1,570
| Boston Scientific | Watchman Access System | $1,228 | 8 payments
|
| Medtronic | Selectsecure | $154 | 1 payment
|
| Amgen | Repatha | $97 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $92 | 1 payment
|
2022: $909
| Novo Nordisk | Rybelsus | $351 | 3 payments
|
| Biotronik | Solia | $134 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $125 | 1 payment
|
| Genzyme | Dupixent | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $124 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $50 | 1 payment
|
2021: $112
| HeartFlow | Ffrct | $48 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $41 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $24 | 1 payment
|
2020: $1,549
| Abbott Laboratories | Ensite Cardiac Mapping System | $1,549 | 12 payments
|
2019: $1,406
| Abbott Laboratories | Ensite Cardiac Mapping System | $1,282 | 14 payments
|
| Amgen | Repatha | $124 | 1 payment
|
Professional record
- NPI
- 1891180006
- Licence
- CA A143869California A143869: Current · expires 2027-12-31
- Trained
- Harvard Medical School, 2015
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-04-03
- NPI last updated
- 2021-06-24
- NPI record certified
- 2021-06-24
This is when the NPI record was last certified, not a medical board exam.